PMA device
Apilgraf(Graftskin)
Organogenesis, Inc. · Dressing, Wound And Burn, Interactive (MGR, Class III) · First FDA decision Jan 17, 2002, newest Jan 17, 2002BurnsChronic wounds and ulcers
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
PMA pathway
Device trials
0
Naming "Apilgraf"
MAUDE reports
0
Brand "Apilgraf", since 2015
PubMed studies
0
Mentioning "Apilgraf"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Apilgraf(Graftskin)
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- APILGRAF(GRAFTSKIN)PMA supplement
P950032-S028 · Decided Jan 17, 2002 · 85 days after receipt · Normal 180 Day Track
Device type: Dressing, wound and burn, interactive (MGR) · General & Plastic Surgery
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Apilgraf", any status and sponsor, newest update first.
No registered device study names "Apilgraf".
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Apilgraf", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code MGR
11 reports: 1 malfunction, 9 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-1747-2011 · Started Feb 21, 2011 · Posted by FDA Mar 23, 2011
Reason given: Product sterility may be compromised
Cause as FDA categorized it: Packaging process control · Device type: Dressing, Wound And Burn, Interactive (MGR)
Z-1746-2011 · Started Jan 30, 2011 · Posted by FDA Mar 23, 2011
Reason given: Product sterility compromised
Cause as FDA categorized it: Material/Component Contamination · Device type: Dressing, Wound And Burn, Interactive (MGR)
Z-2589-2010 · Started Aug 2, 2010 · Posted by FDA Sep 28, 2010
Reason given: Product is contaminated with a yeast identified as Pseudozyma antarctica.
Cause as FDA categorized it: Process control · Device type: Dressing, Wound And Burn, Interactive (MGR)
3 more recall records with a free account
Published research
The most relevant PubMed records for "Apilgraf"[tiab]. The summary above synthesizes these.
No PubMed record mentions this device by name.
Other devices of this type
Also filed under product code MGR.
- ApligrafOrganogenesis, Inc. · PMA 2013
- TranscyteShire Regenerative Medicine · PMA 2004
- DermagraftShire Regenerative Medicine · PMA 2012
- Integra Dermal Regeneration TemplateIntegra Lifesciences Corp. · PMA 2017
- Transcyte Human Fibroblast-Derived Temporary Skin SubstituteShire Regenerative Medicine · PMA 2011
- Orcel Bilayered Cellular MatrixForticell Bioscience · PMA 2001
- Transcyte/Human Fibroblast Derived Temporary Skin SubstituteShire Regenerative Medicine · PMA 2001
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.